2010 Scrip 100 - Little change in win, place or show
This article was originally published in Scrip
Executive Summary
When examining the competitiveness of company pipelines, and the extent of a company's R&D commitment, it is arguably more relevant to consider the number of drug projects as reflected by clinical trials activity as opposed to the overall number of drugs in the pipeline. Clinical trial activity was assessed over the 12-month period from September 2008 to August 2009, using data from TrialTrove where trial start dates were disclosed in the public domain.